51,808 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Nepsis Inc.

Nepsis Inc. purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 51,808 shares of the biotechnology company’s stock, valued at approximately $18,565,000. United Therapeutics comprises 4.4% of Nepsis Inc.’s holdings, making the stock its 10th largest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Veracity Capital LLC acquired a new position in shares of United Therapeutics during the 3rd quarter worth approximately $386,000. Raymond James & Associates grew its stake in shares of United Therapeutics by 1.7% in the third quarter. Raymond James & Associates now owns 35,751 shares of the biotechnology company’s stock valued at $12,811,000 after buying an additional 609 shares in the last quarter. First Citizens Bank & Trust Co. increased its holdings in United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after buying an additional 48 shares during the last quarter. Blue Trust Inc. raised its position in United Therapeutics by 45.1% during the third quarter. Blue Trust Inc. now owns 1,405 shares of the biotechnology company’s stock worth $503,000 after acquiring an additional 437 shares in the last quarter. Finally, Trust Point Inc. lifted its stake in United Therapeutics by 28.3% in the third quarter. Trust Point Inc. now owns 1,166 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 257 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on UTHR. Jefferies Financial Group upped their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Wells Fargo & Company lifted their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. HC Wainwright restated a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a research note on Thursday, August 1st. UBS Group lifted their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $357.17.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $4.38 during midday trading on Friday, reaching $368.43. The company’s stock had a trading volume of 243,247 shares, compared to its average volume of 470,598. The company has a market cap of $16.34 billion, a P/E ratio of 17.42, a P/E/G ratio of 1.30 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $377.03. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The business’s 50 day moving average price is $350.66 and its two-hundred day moving average price is $308.45.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. During the same quarter in the previous year, the company posted $5.24 earnings per share. The business’s revenue was up 19.8% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James Edgemond sold 7,792 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $355.88, for a total value of $2,773,016.96. Following the completion of the sale, the chief financial officer now directly owns 5,884 shares in the company, valued at $2,093,997.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 105,830 shares of company stock worth $36,010,158 over the last ninety days. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.